The ROCKET AF study was a blinded, double-dummy, randomized-controlled trial in which 14,262 patients with nonvalvular AF at increased risk for stroke were assigned to rivaroxaban 20 mg daily (or ...

Future challenges for rivaroxaban uptake in patients with AF include unfamiliarity with management of interruption and bleeding, and cost of the drug. The site of action of rivaroxaban and vitamin ...

rivaroxaban, 0.38 [95% confidence interval {CI}, 0.24 to 0.60]; hazard ratio for 90-mg abelacimab vs. rivaroxaban, 0.31 [95% CI, 0.19 to 0.51]; P<0.001 for both comparisons). The incidence and ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...